Sutro Biopharma (STRO) FCF Margin (2017 - 2025)
Sutro Biopharma (STRO) posted FCF Margin of 403.32% for Q4 2025, up 1.47% sequentially from 409.34% in Q3 2025, and up 9746.0% YoY from 4.1% in Q4 2024.
Powered by 
Analysis
Sutro Biopharma (STRO) FCF Margin (2017 - 2025) Analysis & Trends
Sutro Biopharma has reported FCF Margin for 9 years, with the latest figure at 403.32% in Q4 2025.
- Quarterly FCF Margin rose 9746.0% year-over-year to 403.32% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 183.63% (up 13008.0% YoY) and the FY2025 annual result came in at 174.59%, up 13913.0% from the prior year.
- FCF Margin rose to 403.32% in Q4 2025 per STRO's latest filing, from 409.34% in the prior quarter.
- Over five years, FCF Margin peaked at 269.74% in Q3 2022 and troughed at 751.06% in Q3 2024.
- A 5-year average of 272.39% and a median of 305.42% in 2021 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2024: FCF Margin soared 56556 bps in 2022, then plunged 56621 bps in 2024.
- Over 5 years, FCF Margin stood at 326.06% in 2021, then advanced by 21 bps to 259.14% in 2022, then jumped by 105 bps to 12.47% in 2023, then slumped by 4115 bps to 500.78% in 2024, then rose by 19 bps to 403.32% in 2025.
- According to Business Quant data, FCF Margin over the past three periods registered 403.32%, 409.34%, and 70.15% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 70.82% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -22.35% |
| 10 | Sutro Biopharma | 332.59 Mn | 168.25 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -403.32% |
| Sep 30, 2025 | -396.57% |
| Jun 30, 2025 | -70.30% |
| Mar 31, 2025 | -396.90% |
| Dec 31, 2024 | -491.63% |
| Sep 30, 2024 | -766.95% |
| Jun 30, 2024 | 33.84% |
| Mar 31, 2024 | -501.13% |
| Dec 31, 2023 | 11.11% |
| Sep 30, 2023 | -199.89% |
| Jun 30, 2023 | -315.01% |
| Mar 31, 2023 | -488.66% |
| Dec 31, 2022 | -315.47% |
| Sep 30, 2022 | 258.94% |
| Jun 30, 2022 | -19.17% |
| Mar 31, 2022 | -624.18% |
| Dec 31, 2021 | -226.37% |
| Sep 30, 2021 | -345.23% |
| Jun 30, 2021 | -38.06% |
| Mar 31, 2021 | -223.78% |